1. Home
  2. MLTX vs TPC Comparison

MLTX vs TPC Comparison

Compare MLTX & TPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MLTX
  • TPC
  • Stock Information
  • Founded
  • MLTX 2021
  • TPC 1894
  • Country
  • MLTX Switzerland
  • TPC United States
  • Employees
  • MLTX N/A
  • TPC N/A
  • Industry
  • MLTX Biotechnology: Pharmaceutical Preparations
  • TPC General Bldg Contractors - Nonresidential Bldgs
  • Sector
  • MLTX Health Care
  • TPC Consumer Discretionary
  • Exchange
  • MLTX Nasdaq
  • TPC Nasdaq
  • Market Cap
  • MLTX 2.8B
  • TPC 2.5B
  • IPO Year
  • MLTX N/A
  • TPC N/A
  • Fundamental
  • Price
  • MLTX $54.36
  • TPC $56.97
  • Analyst Decision
  • MLTX Strong Buy
  • TPC Strong Buy
  • Analyst Count
  • MLTX 7
  • TPC 3
  • Target Price
  • MLTX $74.83
  • TPC $60.67
  • AVG Volume (30 Days)
  • MLTX 462.7K
  • TPC 758.4K
  • Earning Date
  • MLTX 08-05-2025
  • TPC 08-06-2025
  • Dividend Yield
  • MLTX N/A
  • TPC N/A
  • EPS Growth
  • MLTX N/A
  • TPC N/A
  • EPS
  • MLTX N/A
  • TPC N/A
  • Revenue
  • MLTX N/A
  • TPC $4,770,779,000.00
  • Revenue This Year
  • MLTX N/A
  • TPC $19.51
  • Revenue Next Year
  • MLTX N/A
  • TPC $15.59
  • P/E Ratio
  • MLTX N/A
  • TPC N/A
  • Revenue Growth
  • MLTX N/A
  • TPC 12.03
  • 52 Week Low
  • MLTX $31.42
  • TPC $18.34
  • 52 Week High
  • MLTX $58.26
  • TPC $63.96
  • Technical
  • Relative Strength Index (RSI)
  • MLTX 57.84
  • TPC 64.85
  • Support Level
  • MLTX $52.02
  • TPC $53.83
  • Resistance Level
  • MLTX $55.81
  • TPC $57.75
  • Average True Range (ATR)
  • MLTX 1.71
  • TPC 2.44
  • MACD
  • MLTX -0.18
  • TPC 0.09
  • Stochastic Oscillator
  • MLTX 71.14
  • TPC 58.29

About MLTX MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.

About TPC Tutor Perini Corporation

Tutor Perini Corp offers general contracting, construction management, and design-build services to private and public customers. The company constructs and repairs transportation infrastructure, water-treatment facilities, and a wide range of buildings. Tutor Perini has three operating segments: Civil, Building, and Specialty Contractors. A majority of its revenue is generated from the Civil segment, which specializes in public works construction and the replacement and reconstruction of infrastructure. Its civil contracting services include construction and rehabilitation of highways, bridges, tunnels, mass-transit systems, military and other government facilities, and water management and wastewater treatment facilities. Geographically, it derives key revenue from the United States.

Share on Social Networks: